Canaccord Genuity Maintains Buy on WAVE Life Sciences, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 56.8%

Neg 56.8% Neu 0% Pos 0%

Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $52 to $43.